GO
Loading...

Pharmaceuticals

More

  • Weekly Leader Current Stats Friday, 27 Apr 2007 | 9:38 AM ET

    Hey folks, we have some info on the weekly leader we can pass along. At this point, the current weekly leader is Alejandro Garcia--tracking at about a 90% gain and is currently all in cash. He has made two trades this week. (This is not to declare ANYONE a weekly winner yet)

  • Old & New Friends for Bristol Thursday, 26 Apr 2007 | 4:34 PM ET

    Bristol-Myers Squibb announced today a potential $1 billion partnership deal with the biggest pharmaceutical company in the world, Pfizer, on a clot-busting drug. And there are signals that its older, troubled partnership with ImClone Systems could be in for some reconciliation.Shares of IMCL were down after the company reported that sales of the cancer drug it markets with BMY, Erbitux, climbed 16% in the first quarter, but fell short of the analyst consensus by $5 million.

  • Roche Reins in Tamiflu Production as Supply Tops Demand Thursday, 26 Apr 2007 | 12:21 PM ET

    Swiss-based Roche said it was cutting production of influenza drug Tamiflu, seen as one of the best defenses against a possible bird flu pandemic, because supply now exceeds demand.

  • Tamiflu Turnaround Thursday, 26 Apr 2007 | 11:35 AM ET

    Is this a sign that the world has become complacent about the pandemic flu threat? Or that some people think it was all a bunch of hooey?Roche today is announcing that it's cutting back production of Tamiflu. When bird flu stories and fears started reaching critical mass more than a year ago, Roche came under considerable criticism for not being able to make enough Tamiflu to meet the sudden spike in demand.

  • Bayer First-Quarter Net Profit Surges Thursday, 26 Apr 2007 | 4:54 AM ET

    Chemical and pharmaceutical maker Bayer on Thursday reported a surge in first-quarter net profit to 2.8 billion euros ($3.82 billion), boosted by one-time gains and strong sales.

  • Depressed Pooch? Eli Lilly Gets FDA Approval for New Drug Wednesday, 25 Apr 2007 | 11:19 AM ET

    Eli Lilly  announced Wednesday it has received approval from the FDA to market Reconcile, the first selective serotonin reuptake inhibitor (SSRI) class of antidepressants approved by the FDA for treatment of canine separation anxiety in conjunction with behavior modification training.

  • Glaxo First-Quarter Profits Down 1%, Hit by Strong Pound Wednesday, 25 Apr 2007 | 9:52 AM ET

    GlaxoSmithKline profits dipped 1% in the first quarter, as sales were hit by the strength of sterling and the loss of patent protection on key medicines, Europe's biggest drugmaker said on Wednesday.

  • Re-Cap: Leaderboard, Most Active And Trivia Tuesday, 24 Apr 2007 | 4:25 PM ET

    Here's our re-cap of today with the leaderboard, most active and widely held as well as the trivia questions. (we have video of all this below). The video question is worth $2,000 Bonus Bucks: According to the Alix Partners brand survey, which company was voted the least trusted brand in America? Your selection of answers is: Microsoft or Kraft or Ford or Sony.

  • Several other major drug companies were apparently interested in buying MedImmune, including Merck, Eli Lilly and possibly Novartis, CNBC’s David Faber reported Tuesday.

  • Contest Stocks: M&A Talk Boosts Best Performers Tuesday, 24 Apr 2007 | 9:46 AM ET

    Here's a look at the latest contest stock action. Mergers and acquisitions played a strong part in the best performers (MedImmune, Baush & Lomb) as well as earnings figures (Angiodynamics). A couple of newer names showed up in the most active list (Ligand and Angiotech) while the widely held stocks stayed the same.

  • KKR Trumps Boots Bidding War; Terra Firma Withdraws Tuesday, 24 Apr 2007 | 9:36 AM ET

    A bidding war for Alliance Boots ended Tuesday with the company's deputy chairman and a private equity firm emerging the winner after a sweetened 11 billion pound ($22 billion) offer pushed a rival private equity group out of the running.

  • Amgen, the world's largest biotechnology company, reported higher first-quarter profit on Monday, driven by increased sales of its anemia and arthritis drugs. Excluding items, the Thousand Oaks, Calif.-based company earned $1.08 a share, matching analysts' average forecast of $1.08 a share, according to Thomson Financial.

  • Hot Stocks: MedImmune, Coal Stocks Among Big Movers Monday, 23 Apr 2007 | 5:33 PM ET

    M&A news and earnings updates provided some of the catalysts for Monday's most actively traded stocks.

  • AstraZeneca to Buy MedImmune for $15 Billion Monday, 23 Apr 2007 | 2:41 PM ET

    AstraZeneca has agreed to buy U.S. biotechnology company MedImmune for more than $15 billion in the biggest transaction since the creation of the Anglo-Swedish drugs group in 1999.

  • Mylan Laboratories spacer said U.S. regulators approved its generic version of Sanofi-Aventis' sleeping pill, Ambien, in the 5 mg and 10 mg strengths.

  • More Embargo-gate & Biotech Lotto Monday, 23 Apr 2007 | 11:56 AM ET

    In a previous blog post, I wrote about what happened at this year's American College of Cardiology conference in New Orleans when at least one doctor "leaked" the results of a major, highly anticipated study comparing drug-coated stents to old-fashioned heart drugs. The ACC had to move up the embargo time of the data by one day and reporters had to scramble to meet the hastened deadline.

  • Demand for a free vaccine against cervical cancer is outstripping supply in New Hampshire, which was the first state in the country to approve free distribution of the vaccine, which protects girls against four strains of a sexually transmitted infection called human papillomavirus, or HPV.

  • Strong sales of its flagship drugs boosted net profit at Swiss drugmaker Novartis by 11% to $2.171 billion, the group said on Monday, confounding expectations for a weaker profit.

  • Hot Stocks: Google, Caterpillar Among Big Movers Friday, 20 Apr 2007 | 1:39 PM ET

    Earnings blowouts from Google and strong guidance from two key names in the industrial sector were among the catalysts for Friday's most-active stocks.

  • The Biotech Lotto Friday, 20 Apr 2007 | 9:54 AM ET

    The average markup or premium paid in a biotech M & A deal worth at least $500 million in 2006 was 60%. 60%! That's one of the most startling numbers you'll find in Ernst & Young's 21st Annual "Global Biotechnology Report".

Most Popular Video

Wednesday, 16 Apr 2014 | 11:11 PM ET

Vasu Menon, VP, Group Wealth Management at OCBC Bank, describes why Asian shares are mixed on Thursday despite dovish comments from the Fed overnight.

Wednesday, 16 Apr 2014 | 9:13 PM ET

Ha Jiming, Vice Chairman, China at Goldman Sachs Private Wealth Management, says China needs structural reforms that can correct imbalances in its economy.

Wednesday, 16 Apr 2014 | 8:55 PM ET

Frank Appel , CEO at Deutsche Post DHL, sees "higher chances than risks" for its business in the mainland despite recent data pointing to a slowdown.